MURAGLITAZAR

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C29H28N2O7
Molecular Weight	516.5418
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

COC1=CC=C(OC(=O)N(CC(O)=O)CC2=CC=C(OCCC3=C(C)OC(=N3)C4=CC=CC=C4)C=C2)C=C1

InChI

InChIKey=IRLWJILLXJGJTD-UHFFFAOYSA-N

InChI=1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33)

HIDE SMILES / InChI

Molecular Formula	C29H28N2O7
Molecular Weight	516.5418
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Muraglitazar previously known as BMS-298585 has been identified as a non-thiazolidinedione dual agonist of peroxisome proliferator-activated receptor alpha/gamma. Muraglitazar is currently in clinical trial phase III development for the treatment of type 2 diabetes and dyslipidemia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Peroxisome proliferator-activated receptor alpha 62	Agonist 2,752		320.0 nM [EC50]
Peroxisome proliferator-activated receptor gamma 118	Agonist 2,752		110.0 nM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 262	Primary		Phase III 665	Unknown
Dyslipidemia 34	Primary		Phase III 665	Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
1.8 μg/mL	10 mg single, oral		MURAGLITAZAR plasma	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
12 μg × h/mL	10 mg single, oral		MURAGLITAZAR plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
35.1 h	10 mg single, oral		MURAGLITAZAR plasma	Homo sapiens

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P007HMK	https://www.1pchem.com/search?query=1P007HMK
Angene	AGN-PC-04XYUX	http://www.angenechemical.com/productshow/AGN-PC-04XYUX.html
ApexBio Technology	C3986	https://www.apexbt.com/catalogsearch/result/?q=C3986
Cayman Chemical	10007853	http://www.caymanchem.com/app/template/Product.vm/catalog/10007853
eMolecules	10595085	https://orderbb.emolecules.com/search/#?query=10595085

Showing 1 to 5 of 11 entries

Previous1 2 3Next

PubMed

Show entries

Title	Date	PubMed
Gateways to clinical trials.	2004 Sep	15538546
Muraglitazar (Bristol-Myers Squibb/Merck).	2005 Apr	15898350
Meeting highlights. 65th annual scientific sessions of the American Diabetes Association, San Diego. Dual PPAR agonist improves glycemic control, lipids in type 2 diabetes.	2005 Aug	16104078
Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.	2005 Sep	16341289
K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome.	2006	22500152

Showing 1 to 5 of 28 entries

Previous1 2 3 4 5 6Next

Patents

Sample Use Guides

In Vivo Use Guide

This was a randomized, double-blind, placebo-controlled, parallel-group, multicenter, 24-week monotherapy study in drug-naive, type 2 diabetes patients with inadequate glycemic control. Men and women aged 18 to 70 years with a body mass index < or =41 kg/m(2) and serum triglyceride levels < or =600 mg/dL were eligible for study participation. The study included double-blind and open-label treatment phases. Patients with glycosylated hemoglobin (HbA(1c)) levels > or =7.0% and < or =10.0% at screening were enrolled in the double-blind treatment phase. These patients received treatment with muraglitazar 2.5 mg, muraglitazar 5 mg, or placebo.

Route of Administration: Oral

In Vitro Use Guide

Muraglitazar/BMS-298585 (2) has been identified as a non-thiazolidinedione PPAR alpha/gamma dual agonist that shows potent activity in vitro at human PPARalpha (EC(50) = 320 nM) and PPARgamma(EC(50) = 110 nM).